BioAtla, Inc. (BCAB) DCF Valuation

BioAtla, Inc. (BCAB) DCF Valuation

US | Healthcare | Biotechnology | NASDAQ
BioAtla, Inc. (BCAB) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

BioAtla, Inc. (BCAB) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Explore the financial potential of BioAtla, Inc. (BCAB) with our user-friendly DCF Calculator! Enter your assumptions regarding growth, margins, and expenses to calculate the intrinsic value of BioAtla, Inc. (BCAB) and enhance your investment strategy.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 5.2 .4 .3 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 -91.75 -41.72 -100 0 -58.37 -58.37 -58.37 -58.37 -58.37
EBITDA -27.4 -33.5 -94.1 -106.5 -122.2 .0 .0 .0 .0 .0
EBITDA, % -526.25 -7798.6 -37627.6 100 100 -20 -20 -20 -20 -20
Depreciation .9 1.0 1.3 1.2 1.2 .0 .0 .0 .0 .0
Depreciation, % 16.54 234.97 532 100 100 83.31 83.31 83.31 83.31 83.31
EBIT -28.2 -34.5 -95.4 -107.7 -123.5 .0 .0 .0 .0 .0
EBIT, % -542.79 -8033.57 -38159.6 100 100 -20 -20 -20 -20 -20
Total Cash 3.7 238.6 245.0 215.5 111.5 .0 .0 .0 .0 .0
Total Cash, percent .0 .1 .1 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 0 0 0 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 0 0 0 100 100 40 40 40 40 40
Accounts Payable 5.1 2.5 1.2 4.2 3.8 .0 .0 .0 .0 .0
Accounts Payable, % 98.83 572.49 471.6 100 100 99.77 99.77 99.77 99.77 99.77
Capital Expenditure -1.5 -.6 -.9 -.3 -.1 .0 .0 .0 .0 .0
Capital Expenditure, % -29.02 -137.53 -369.6 100 100 -45.8 -45.8 -45.8 -45.8 -45.8
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -29.7 -35.8 -95.4 -106.5 -123.5 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -25.2 -38.1 -96.3 -102.5 -122.8 -3.8 .0 .0 .0 .0
WACC, % 8.9 8.9 8.9 8.89 8.9 8.9 8.9 8.9 8.9 8.9
PV UFCF
SUM PV UFCF -3.5
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -4
Net Debt -109
Equity Value 106
Diluted Shares Outstanding, MM 48
Equity Value Per Share 2.21

What You Will Receive

  • Authentic BioAtla Data: Preloaded financial metrics – from revenue to EBIT – based on actual and forecasted figures for BioAtla, Inc. (BCAB).
  • Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates to suit your analysis.
  • Immediate Valuation Adjustments: Automatic recalculations to evaluate the effects of changes on BioAtla’s fair value.
  • Flexible Excel Template: Designed for quick modifications, scenario analysis, and in-depth projections.
  • Efficient and Precise: Avoid the hassle of building models from the ground up while ensuring accuracy and adaptability.

Key Features

  • Customizable Clinical Data Inputs: Adjust vital parameters such as trial success rates, projected revenue, and R&D expenses.
  • Instant DCF Analysis: Automatically computes intrinsic value, NPV, and other financial metrics in real-time.
  • High-Precision Valuation: Leverages BioAtla's (BCAB) actual financial data for accurate valuation results.
  • Effortless Scenario Testing: Evaluate various assumptions and analyze different outcomes with ease.
  • Efficiency Booster: Streamlines the valuation process, removing the need for intricate model creation from scratch.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review BioAtla, Inc.'s pre-filled financial data and forecasts.
  3. Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
  4. Step 4: Watch the DCF model update instantly as you tweak assumptions.
  5. Step 5: Analyze the outputs and use the results for investment decisions regarding BioAtla, Inc. (BCAB).

Why Choose This Calculator for BioAtla, Inc. (BCAB)?

  • User-Friendly Interface: Tailored for both novices and seasoned professionals.
  • Customizable Inputs: Modify parameters effortlessly to suit your financial analysis.
  • Real-Time Valuation: Observe immediate updates to BioAtla's valuation as you tweak inputs.
  • Preloaded Data: Comes with BioAtla’s actual financial information for swift evaluations.
  • Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.

Who Should Use This Product?

  • Investors: Evaluate BioAtla’s (BCAB) intrinsic value to support informed investment choices.
  • CFOs: Utilize a high-caliber DCF model for precise financial reporting and analysis.
  • Consultants: Seamlessly customize the template for client valuation reports.
  • Entrepreneurs: Acquire knowledge on financial modeling techniques employed by leading biotech firms.
  • Educators: Employ it as a resource to illustrate valuation strategies in the classroom.

What the Template Contains

  • Pre-Filled DCF Model: BioAtla’s financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate BioAtla’s profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

No products were found matching.